Sun Pharmaceutical Industries Limited, established by Dilip Shanghvi in 1983 in Calcutta, West Bengal, with five psychiatry products and a two-person marketing team, has grown into a leading specialty generic company worldwide. Sun Pharma is the No. 1 pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The company reports global revenue of US$ 5.8 billion, with trailing 12-month revenue of $6.15B as of March 2025.
Sun Pharma manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries. Around 70% of Sun Pharma's revenue is generated from international markets, with the US and India being the largest markets, accounting for over 60% of the company's turnover. The company is supported by 41 manufacturing facilities, providing high-quality medicines trusted by healthcare professionals and patients across the globe.
Manufacturing operations are spread across 43 locations in India, the US, Asia, Africa, Australia, and Europe. In the U.S., Sun Pharma is among the leading specialty generic companies and is ranked No. 2 in generic dermatology by prescriptions. The company employs 19,530 total employees globally.
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The therapeutic segments covered by the company's portfolio of over 2000 molecules include psychiatry, anti-infectives, neurology, cardiology, orthopedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental, and nutritionals.
The key segments being targeted are dermatology, ophthalmology, and oncology. Sun Pharma specializes in differentiated products including liposomal drugs, inhalers, lyophilized injections, nasal sprays, and controlled-release dosage forms, showcasing its strong focus on innovation. The company offers medications in multiple dosage forms, such as injectables, sprays, ointments, creams, liquids, tablets, and capsules.
Sun Pharma was the first among Indian pharmaceutical companies to realize and embrace the importance of innovation, investing 6–8% of global revenues annually into Research and Development (R&D). The company has a team of over 3,000 R&D personnel with strong intellectual capabilities in formulations, process chemistry, and analytical development.
Based on the latest available financial data:
FY 2024-25 Annual Results:
* Sales rose 8.97% to ₹52,041.25 Crore in the year ended March 2025, as against ₹47,758.45 Crore during the previous year ended March 2024.
* Net profit rose 14.12% to ₹10,929.04 Crore in the year ended March 2025, as against ₹9,576.38 Crore during the previous year ended March 2024.
Q4 FY 2024-25 Results:
* Sales rose 8.48% to ₹12,815.58 Crore in the quarter ended March 2025, as against ₹11,813.33 Crore during the previous quarter ended March 2024.
* Net profit declined 19.01% to ₹2,149.88 Crore in the quarter ended March 2025, as against ₹2,654.58 Crore during the previous quarter ended March 2024.
Q3 FY 2024-25 Results:
* Consolidated revenue from operations reached ₹13,675.46 Crore, marking an increase from ₹12,380.70 Crore in the same quarter of the previous year.
* Net profit after tax amounted to ₹2,912.98 Crore compared to ₹2,560.54 Crore in the corresponding quarter last year.
Market Capitalization:
Market Cap: ₹4,02,201 Crore as of current date.
In January 2024, Sun Pharma entered into a definitive merger with Taro Pharmaceuticals to acquire the remaining stake in Taro Pharma for $347.73 million. In March 2025, it was announced Sun Pharma had acquired the Waltham, Massachusetts-headquartered immunotherapy and targeted oncology treatment company, Checkpoint Therapeutics, for $355 million.
The most significant acquisition was in April 2014, when Sun Pharma announced the acquisition of Ranbaxy Laboratories in a US$4 billion transaction to create the world's fifth-largest specialty generic pharmaceutical company by sales.
Sun Pharmaceutical Industries has fixed July 7, 2025, as the record date for payment of a final dividend of ₹5.50 per share for FY 2024-25, with the dividend to be paid on or before August 8, 2025, if approved.
Sun Pharmaceutical Industries Limited continues to strengthen its position as a leading global pharmaceutical company through strategic acquisitions, robust R&D investments, and expanding its presence in key therapeutic areas while maintaining its commitment to providing high-quality, affordable medicines worldwide.
